Analyst Price Targets — LKFT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 11, 2026 12:25 pm | Judah Frommer | Morgan Stanley | $26.00 | $28.01 | TheFly | Lakefront Biotherapeutics price target lowered to $26 from $30 at Morgan Stanley |
| July 10, 2026 9:29 am | — | Morgan Stanley | $30.00 | $30.59 | TheFly | Lakefront Biotherapeutics resumed with an Equal Weight at Morgan Stanley |
Latest News for LKFT
Mechelen, Belgium; 01 September 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that between August 24, 2026 and August 28, 2026 it has repurchased 127,796 Lakefront shares via a discretionary mandate to an independent financial intermediary, as follows: Date of purchase…
Mechelen, Belgium; 25 August 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that between August 17, 2026 and August 21, 2026, it has repurchased 117,471 Lakefront shares via a discretionary mandate to an independent financial intermediary, as follows: Date of purchase…
Mechelen, Belgium; 24 August 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to gamgertamig for the treatment of pemphigus. Gamgertamig was previously granted both Fast Track and Orphan Drug Designation by the U.S. FDA for the treatment of autoimmune hemolytic anemia…
Mechelen, Belgium; August 24, 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) received a transparency notification from Bank of America.
Mechelen, Belgium; 18 August 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that between August 10, 2026 and August 14, 2026, it has repurchased 107,871 Lakefront shares via a discretionary mandate to an independent financial intermediary, as follows: Date of purchase…
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for LKFT.
Senate Trading
No Senate trades found for LKFT.
U.S. House Trading
No House trades found for LKFT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.